Research & Development

Caris Life Sciences™ is focused on the development of a highly-accurate and precise blood-based diagnostics platform to provide patients with more detailed information at earlier stages of their disease. The minimally invasive clinical tests developed on this platform will address many unmet clinical needs across the cancer spectrum — from screening and diagnosis to prognosis and therapeutic guidance — enabling physicians to provide patients with precise and effective treatment.

The Caris Research & Development team has performed critical research across a number of tumor types and disease states to uncover biosignatures that will enable the earlier detection and more effective management of disease. The assays developed on this platform are more sensitive and specific than current testing methods and will help reduce the morbidity associated with unnecessary follow-up procedures. Caris also anticipates this blood-based technology will help facilitate longitudinal studies to monitor disease status and responsiveness to therapy.

Caris is currently partnering with leading universities and research institutions to bring this cutting-edge diagnostic technology to patients. The company's expertise in commercializing molecular profiling tests, combined with trusted relationships with thousands of physicians across the nation, makes Caris the partner of choice for molecular diagnostic testing and development.